Osteoporosis

Once-yearly Reclast Significantly Reduced Bone Fractures in Women with Postmenopausal Osteoporosis

Published in Lab Law Weekly, May 18th, 2007

A once-yearly treatment of Reclast(R) (zoledronic acid) Injection significantly reduced the incidence of all types of osteoporotic bone fractures over three years in women with postmenopausal osteoporosis. This study, published today in The New England Journal of Medicine, marks the first time that an osteoporosis treatment significantly reduced all types of fractures in a single study.

Reclast is a bisphosphonate, a class of drugs used to treat osteoporosis, the most common metabolic bone disease affecting more than 10 million people in the US(1). An estimated one out of every two women over age 50 will suffer a broken bone in her lifetime (1).

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Lab Law Weekly

Source: Lab Law Weekly (2007-05-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry